PSC
NBIX icon

Piper Sandler & Co’s Neurocrine Biosciences NBIX Stock Holding History

Piper Sandler & Co’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-8,000
Closed -$318K – 57
2015
Q3 		$318K Buy
+8,000
New +$387K 0.34% 38

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Piper Sandler & Co's NBIX Position: Q4 2015 in Review

Piper Sandler & Co sold out of Neurocrine Biosciences (NBIX) in Q4 2015, closing a stake of 8,000 shares — an estimated $318K sold.

Piper Sandler & Co first reported a position in NBIX in Q3 2015 and held it in 1 quarter. The position peaked at $318K in Q3 2015. 218 funds tracked by Wall St. Rank hold NBIX as of Q4 2015.

  • Piper Sandler & Co reported no remaining Neurocrine Biosciences position as of Q4 2015 after selling out during the quarter.
  • Piper Sandler & Co sold 8,000 Neurocrine Biosciences shares in Q4 2015, an estimated $318K.
  • Piper Sandler & Co first reported a position in Neurocrine Biosciences in Q3 2015 and held it in 1 quarter.
  • Piper Sandler & Co's Neurocrine Biosciences position peaked at $318K in Q3 2015.
  • 218 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2015.

Based on Piper Sandler & Co's 13F filing for Q4 2015, filed 16 Feb 2016.